Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally.
$19.10-0.73%
报价 2026-11-06
市值
$1.38B
EV
$1.13B
PE (TTM)
6.0x
预期 PE (FY2026)
7.9x
52 周区间距高点 -21.2%
$19.10$24.24
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| INVAInnoviva, Inc. | $1.38B | -0.7% | +10.3% | 78.9% | 6.0x | 3.0x | 8.2x | |
| DNTHDianthus Therapeutics, Inc. | $4.81B | +3.6% | -45.5% | 94.3% | – | – | – | |
| RLAYRelay Therapeutics, Inc. | $4.08B | +9.4% | -14.8% | 89.7% | – | – | – | |
| ELVNEnliven Therapeutics, Inc. | $3.62B | +10.4% | – | 0% | – | – | – | |
| INBXInhibrx Biosciences, Inc. | $1.24B | +5.3% | +230.8% | 0% | – | – | – | |
| NKTRNektar Therapeutics | $1.07B | +3.1% | -5.3% | 99.4% | – | – | – | |
| IMTXImmatics N.V. | $951.7M | +2.9% | – | 100% | – | – | – | |
| SNDXSyndax Pharmaceuticals, Inc. | $858.9M | +1.8% | +107.0% | 96% | – | – | – | |
| MDXGMiMedx Group, Inc. | $483M | +0.9% | -30.8% | 82.6% | 12.9x | 6.0x | 6.9x | |
| 同行中位数 | – | – | -10.1% | 92% | 12.9x | 6.0x | 6.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。